Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

120 1,962 1,366 5,144 -------- -------- -------- -------- Total revenues 1,412 6,350 10,700 32,321 Operating expenses: Research and development, including stock-based compensation of $694, $1,028, $3,022 and $3,941, respectively 18,834 22,364 81,238 107,232 General and administrative, including stock-based compensation of $502, $691, $2,252 and $2,559, respectively 4,425 4,875 19,418 21,624 -------- -------- -------- -------- Total operating expenses 23,259 27,239 100,656 128,856 -------- -------- -------- -------- Loss from operations (21,847) (20,889) (89,956) (96,535) Gain (loss) on investments, net 165 2,008 1,173 (1,314) Interest income 211 607 880 5,762 Interest expense (786) (671) (2,966) (2,691) Other expense, net (513) (485) (2,550) (2,106) -------- -------- -------- -------- Consolidated loss before income taxes (22,770) (19,430) (93,419) (96,884) Income tax benefit - - 102 - -------- -------- -------- -------- Consolidated net loss (22,770) (19,430) (93,317) (96,884) Loss attributable to noncontrolling interest in Symphony Icon, Inc. 765 4,013 10,537 20,024 -------- -------- -------- -------- Net loss attributable to Lexicon Pharmaceuticals, Inc. $(22,005)
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... FORT WORTH, Texas, Nov. 5 Wound Management Technologies, Inc., ... of Intent to purchase all healthcare-related assets of Virtual Health ... VHGI to be paid $1,000,000 in cash and debt, 4,000,000 ... by WNDM on the Veriscrip technology being acquired from VHGI. ...
... ... Drug safety specialty firm BioSoteria announced that its Vice ... and Performance™ (CPLP) credential from the American Society for Training and ... years of medical communications and health care training experience and is ...
... DIATHERIX Laboratories, Inc. (DIATHERIX) ( www.DIATHERIX.com ... Network Homeland Security Market Leadership Conference in Dearborn, ... of DIATHERIX, explained the impact of the company,s ... infectious disease diagnosis and military efforts. , ...
Cached Biology Technology:OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4DIATHERIX Laboratories Presents at Homeland Security Conference 2
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
(Date:4/17/2014)... in Europe, Asia and the United States are spreading ... impacting native honeybee populations at this time, according to ... including Nosema microsporidia and Varroa ... to these invasive pests, which suggests to us that ... and the United States currently are not necessary in ...
(Date:4/17/2014)... Sodium channels are implicated in many serious conditions such ... important potential target for drug therapies. Unfortunately, there is ... New Cambridge research provides fresh and unexpected insight into ... its components - β-subunit molecules - which are responsible ... is published in the most recent edition of the ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2
... BETHESDA, Md., July 6, 2010 It,s safe to ... smooth surfaces of most mammalian cells, have long been misunderstood ... whiplike cousins flagella, which propel sperm, one type of cilia ... cilia reaching up like concertgoers supporting a crowd-surfer.) But for ...
... of Cell Metabolism , a Cell Press publication, are ... from high levels of triglycerides. High triglycerides are a risk ... to inflammation of the pancreas, the researchers said. The ... University of California, Los Angeles, has identified the component responsible ...
... Last week, at the fourth annual Clinical Trials in Emerging ... and Data Management at Aeras Global TB Vaccine Foundation, and ... the application of the latest in clinical data technology to a ... presentation provided an update on how effective technology can be in ...
Cached Biology News:Researchers demystifying complex cellular communications hubs found in sensory neurons 2Researchers demystifying complex cellular communications hubs found in sensory neurons 3Study sheds light on triglyceride metabolism 2Pioneering Use of Mobile Technology to Conduct Clinical Trials in Emerging Economies 2Pioneering Use of Mobile Technology to Conduct Clinical Trials in Emerging Economies 3
... Plus Microsphere/Microarray Stabilizer is an aqueous solution ... other non-toxic chemicals in a PBS buffer ... This product contains a combination of ... preservative. StabilCoat Plus Stabilizer provides optimum ...
... Domain GenBank Accession Number : ... to residues 77-299 of human-PSD-95 (PDZ ... 0.075M NaCl containing 0.05% sodium azide ... on rat brain microsomal protein preparation ...
... the state-of-the-art in permanent mounting media. ... preservation of immunohistochemical organic insoluble substrates ... New Fuchsin, and any other organic ... sections. Clarin can be used for ...
... is a direct antibiotic-based ... identification. Recombinant selection depends ... eliminating the need for ... quick and inexpensive process ...
Biology Products: